- Details
- Description
About Vebreltinib
Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer . Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.
- Vebreltinib sold as brand name 万比锐® in china.
China’s National Medical Products Administration (NMPA) has granted conditional marketing approval to vebreltinib (APL-101; PBL-1001) for the treatment of patients with non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations.
China’s National Medical Products Administration (NMPA) has approved vebreltinib (APL-101; PLB-1001) for the treatment of patients with IDH-mutant, World Health Organization grade 4 astrocytoma or glioblastoma who harbor PTPRZ1-MET (ZM) fusions, have a history of low-grade disease, and have progressed on prior treatments.
